Anti-VEGF Antibodies: Global Technology Assessment, Market Analysis and Future Growth Trends Due to rapid advancements in genetic sequencing and the translation of basic medical sciences research into clinical practice, humanized mAbs have turn out to be the fastest growing group of biotechnology-derived molecules in clinical trials. Driven by the growing application area pertaining to target disease viz. cancers, autoimmune disorders, infectious diseases, the monoclonal antibody market was valued over US$ 100 billion in 2017 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of xx% to reach US$ xx by the year 2023. Although various small molecule kinase inhibitors have been approved for targeting VEGF induced signaling, the use of mAbs against VEGF has been established since FDA approval of Bevacizumab (Avastin, Genentech/Roche) in the year 2004. Since, Avastin, FDA has approved ranibizumab (Lucentis, Genentech/Roche) and aflibercept (Eylea, Regeneron Pharma) both for cancer treatment and age-related macular degradation (AMD). Therefore, use of mAbs in targeting VEGF induced angiogenesis in cancer, inflammation, arthritis, and AMD have tremendous potential in near future. Download free sample: http://www.iebrain.com/reports/healthcare-biotechnology/anti-vegfantibodies-global-technology-assessment/ Table of Contents: 1.
Technology Overview
2.
Anti-VEGF antibodies: Technology Segmentation
3.
Anti-VEGF antibodies: Global IP Trends
4.
Anti-VEGF antibodies: Different diseases targeted
5.
Anti-VEGF antibody: White Space Analysis
6.
Recent activities in the development of anti-VEGF antibody
7.
Anti-VEGF Antibody Technology Opinions from Experts
8.
Anti-VEGF Antibody Technology Collaboration Insights
9.
Strategies of Companies involved in the development of Anti-VEGF antibody
10. Recent Anti-VEGF Antibody Product Developments 11. Global Trends Anti-VEGF Antibody Market 12. Global Anti-VEGF antibody development: Top Industrial Players 13. Anti-VEGF Antibody – Market Determinants 14. Anti-VEGF Antibody -Opportunity Vs. Restraints 15. Anti-VEGF Antibody: Strategic Analysis SWOT & PEST 16. Anti-VEGF Antibody Market Development (2017-2022) 17. Conclusion Click here for more insights: Reports
About Us: At Ingenious eBrain, we believe that humans assisted with machine intelligence can deliver unparalleled results. Our proprietary in-house tools use the power of AI to deliver the most reliable results in half the time used by traditional methods. The AI assisted workflow allows cost-efficient decision making for even the most challenging problems. Contact Us @ Email Id: services@iebrain.com Contact No: +1347480205